Autres langues Theracryf Plc

Actions

EVG

GB00BSVYN304

Recherche biotechnologique et médicale

Temps Différé London S.E. 08:59:59 06/10/2026			Varia. 5j.	Varia. 1 janv.
0,1800 ^GBX	0,00%		+2,86%	-10,00%

02/10	La marque sans gluten Tooru obtient un nouveau référencement	AN
28/09	Transcript : Theracryf Plc, 2026 Earnings Call, Sep 28, 2026

Autres langues

02/10	Tooru gluten-free brand secures news listing
28/09	EARNINGS: US Solar Fund eyes "modest" fourth-quarter dividend
28/09	Theracryf Plc Reports Earnings Results for the Full Year Ended March 31, 2026
20/08	Theracryf's fund raise; Potter & Moore sales struggle
14/05	Theracryf : Turner Pope Investments – Top-line Toxicology Data
14/05	EARNINGS & TRADING: Nexus Infrastructure first-half loss narrows
14/05	Shares up as Strait of Hormuz talks lift mood
14/05	WINNERS & LOSERS: Auction upgrades guidance; Aquila talks break down
21/04	Theracryf : Turner Pope Investments – TheraCryf plc Research Note
20/04	Catenai renews contract; Angus sees production uplift
20/04	TheraCryf Advances Orexin-1 Addiction Program Toward Phase 1 Trials
14/04	FTSE 100 flat as oil slips below USD100
14/04	WINNERS & LOSERS: James Cropper sees earnings up; Block sells stake
14/04	Theracryf : Turner Pope Investments – indicative proposal for Ox-1 / DAT programmes
14/04	Theracryf : Capital Access Group – Ox-1/DAT programmes – indicative proposal
14/04	TheraCryf Rejects Nonbinding Proposal for Lead Neuropsychiatry Assets
14/04	Theracryf receives non-binding proposal to acquire Theracryf's assets
13/04	Theracryf : Capital Access Group – Orexin M&A demonstrates industry appetite
23/03	EARNINGS AND TRADING: Pennant eyes return to break-even this year
23/03	Theracryf : Capital Access Group – Ox-1 Imminent start of final toxicology study
23/03	TheraCryf Completes Preclinical Dose Range Finding Studies for Ox-1 Addiction Program
23/03	TheraCryf's Ox-1 programme advances to final toxicology study
26/01	EARNINGS AND TRADING: Scancell gets FDA clearance for phase 3 trial
26/01	TheraCryf Secures Notice of Allowance for Orexin-1 Addiction Program in Canada
26/01	Theracryf plc Receives Notice of Allowance from the Canadian Patent Office for Its Orexin-1 Addiction Programme